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Many drugs are administered in the form of liquid-dispersed nanoparticles. Frequently, one of the overlooked aspects in the
development of this drug delivery system is the loss of efficacy and the degradation of the carried drugs. Estimating the shelf life
of drug products implies the storage of samples under controlled conditions of temperature and humidity for different periods,
ranging from months to years, delaying decisions during development, manufacturing, and commercialization. Adapting well-
known isothermal and nonisothermal methods to nanoparticles would allow correlating kinetic parameters obtained in a single
mathematical model and predicting the shelf life faster than traditional methods. Unlike the traditional approaches, the
isoconversional method (i) considers drug products as heterogeneous systems, without a unique kinetic order, (ii) establishes a
maximum percentage of degradation, (iii) assumes the same kinetics for all processes regardless of the conditions, and (iv)
includes the influence of humidity by a modification of Arrhenius equation. This method serves in calculating the kinetic
parameters and shelf life derived from them, in a few weeks. In the same way, nonisothermal treatments allow obtaining these
parameters by differential scanning calorimetry. Samples are subjected to different heating rates to establish the temperature at
which the thermal decomposition event occurs and, thus, to calculate in a few days the activation energy and the preexponential
factor using the Kissinger method. But this approach has limitations: the isoconversional method does not consider crystalline
state of the sample, while nonisothermal method ignores the effect of the storage conditions. Processing nanoparticles for
isothermal and nonisothermal treatments would allow accurate and fast prediction of the drug-loaded nanoparticle shelf life
correlating parameters obtained using a single mathematical model. The accuracy of the prediction would be assessed by
comparison of estimated shelf life versus data coming from traditional stability studies.
1. Introduction
1.1. Nanoparticles as Drug Carriers. Nanotechnology offers
different solutions in the development of new therapeutic
strategies for the treatment of diseases where traditional
solutions have already failed. As an important specific
application, nanomedicine emerged, this is a new science
with diverse therapeutic possibilities for the development
of new treatments [1].
Many drugs are frequently supplied in the form of
nanoparticles dispersed or not in a liquid for consumption.
These particles have diameters in the range of one to several
hundred nanometers and are presented in colloidal forms.
Poorly soluble drugs that have an average particle size
between 200 and 600nm are stabilized in suspension by sur-
factants and/or polymers in a dispersion media. In crystalline
nanosuspensions, the drug is maintained with a decreased
particle size and an increased surface area leading to a higher
rate of dissolution [2] and thus better bioavailability. Nano-
particles intended for oral administration are often presented
in nanosuspensions, commonly transformed into a solid
paste to prevent sedimentation, cremation, and crystal
growth. This facilitates drug administration, patient comfort,
and medication compliance [2].
One of the main problems of nanoparticles in suspension
is the great difference that they present in the saturation
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solubility and the concentration gradient that can give rise to
Ostwald maturation (small crystal dissolution to increase size
of larger crystals). The process of producing nanoparticles
can lead to (i) a crystalline or amorphous product, (ii) a mix-
ture of both, or even (iii) a disordered phase. Amorphous
nanoparticles are prone to particle growth due to Ostwald
maturation; on the other hand, it can be highly unstable in
the presence of small amounts of crystalline particles. In
addition, the high surface energy of these particles triggers
agglomeration of the drug crystals. These phenomena can
be controlled by the addition of various additives to ensure
adequate stabilization. The main function of the stabilizer is
to coat the drug particles to prevent Ostwald maturation
and agglomeration of the nanosuspension and to achieve a
physically stable formulation by providing a steric or ionic
barrier. Suitable wetting of drug particles as well as their
electrostatic and steric stabilization by excipients is necessary
to produce stable nanosuspensions [3, 4].
As it happens for many other nanoparticles of different
natures, the industrial production of pharmaceutic nano-
particles is also carried out through two basic approaches:
(i) bottom-up, upstream process and (ii) top-down, down-
stream process. The first consists of controlled precipitation
or crystallization to make nanoparticles of desired size from
the molecular state, while the latter technologies consist of
mechanical wear of large drug powder into smaller particles.
The relationship of production process in the stability of
nanoparticles is not yet completely clarified, but it is highly
probable that processes requiring high levels of mechanical
energy, like top-down ones, affect the most.
To improve nanoparticle bioavailability, it is of prime
importance to control their extent of dispersion and, there-
fore, an encapsulation process is required. In this respect,
drug nanoparticles can be straightforwardly encapsulated in
the presence of polymers, surfactants, and both. These poly-
meric nanoparticles have been extensively investigated in
both pharmaceutical and medical fields because their subcel-
lular size and biocompatibility with tissue and cells can serve
in controlling their release properties in vivo. The most com-
mon methods to elaborate polymeric nanoparticles are based
on solvent-based encapsulation such as selective nanopreci-
pitation in the presence of surfactants. It is now clear that
the stability of heterogeneous particulate systems depends
on the number of components. As the number of compo-
nents increases, greater is the possibility of negative interac-
tions of a physical or chemical type with deleterious effects
over the stability of the particle.
Most of the characterization processes are performed in
nanoparticle dispersions. These analyses are carried out in a
very similar way to traditional studies, where the particle size,
appearance, color, odor, and related impurities are analyzed.
In addition, dispersion is also evaluated for zeta potential,
crystalline state, dissolution, and in vivo efficacy. For an
electrostatically stabilized nanodispersion, a suitable zeta
potential is above +30mV or below −30mV and for a static
and electrostatic stabilization, it must be above +20mV and
below −20mV. Dynamic light scattering (DLS) is a fast and
sensitive method, especially for determining particle sizes
that are in the nanometer range, requiring only a small
amount of particles. Therefore, it is very suitable for routine
measurements and development of early formulation, when
only small amounts of API are available [5].
1.2. Stability Test for Drug Delivery Systems. Determining the
stability of a pharmaceutical compound in the form of nano-
particles is critical in terms of safety and efficacy. These tests
serve to recommend ideal storage conditions and to establish
the effect of out-of-specification results or deviations on the
manufacturing process. This will ultimately affect the safety,
efficacy, or quality of a drug in the short term, medium term,
or long term.
There are different stability tests to determine the shelf
life of pharmaceutical forms. Official guidelines—such as
those recommended by International Conference of Har-
monization, ICH Q1A (R2), Stability Testing of New Drug
Substances and Products (2003)—describe an isothermal
process, where the sample is subjected to constant temper-
ature and humidity conditions for a minimum period of
12 months in the case of long-term studies and 6 months
for accelerated studies in order to determine the decreas-
ing content of active principle during degradation, as well
as changes in other parameters specific to the performance
of the product such as degradation products, dissolution
test, and appearance.
Traditional stability methods are based on the application
of mathematical models that come from the kinetic theory of
gases to wide variety of liquid, semisolid, and solid drug
products. These tests are applied at different stages of drug
product life cycle. In early stages, extreme conditions of tem-
perature and humidity are investigated, not only to identify
the degradation products that can be found in long-term
storage but also to select the most promissory drug candi-
dates. Other studies are also carried out a posteriori under
less severe conditions to predict the shelf life of products.
In addition to these tests, real-time stability tests are
performed over long periods (months to years).During these
studies, the evolution of the degradation process is measured
sampling at different time points. The reliability of data
interpretation can be increased by including a batch of
reference material, the characteristics of which have already
been established.
In accelerated stability tests, samples are subjected to
relatively high temperatures in order to cause an increase in
degradation rate, in an attempt to reduce the time necessary
to take decisions over safety, efficacy, and quality of medi-
cines. These methods are used to predict drug shelf life or
for comparison with alternative formulations. The most used
is Arrhenius method, which determines the variation of the
kinetic constant as a function of temperature; its application
requires knowing the kinetic order of reaction.
1.3. Kinetics in Heterogeneous Drug Delivery Systems. The
study of the rapidity of physical and chemical transforma-
tions is of great importance, since it has uses in many fields
of industry, pharmacy, or chemistry, both in its processing
conditions and in the storage of raw materials and products.
Most pharmaceutical nanoparticulated systems are highly
complex and not homogeneous at molecular or atomic levels,
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so approaches based on gas kinetic theory which assumes that
each reactant molecule is surrounded mostly by vacuum
probably are not the best. The transformations of substances
in such systems comprise changes in physical state, crystalli-
zation, melting, solubility, chemical reactions, etc. that can
be thermally stimulated by heating or cooling processes. The
speed and form towhich they are transformed are determined
by the kinetic characteristic of the system [2].
The classical method of assessing pharmaceutical stabil-
ity has three main problems that must be considered: First,
a mathematical model that attempts to match the kinetics
of solid substances must be created. The second element to
be considered is the effect of relative humidity on the reaction
kinetics, and the third lies essentially in the time required to
perform the determination of stability [6].
From the classical perspective, chemical reactions can be
fitted into a mathematical model with a certain kinetic order.
Nevertheless, this approach may be appropriate when deal-
ing with homogeneous systems, such as chemical reactions
that occur in gaseous or liquid solution where the intensity
at which the reaction takes place is a function of the total
molecules present in the volume occupied by the system, in
other words, the kinetic equations are expressed as a function
of the concentration of the reactants. In the case of a hetero-
geneous system, a substance that reacts with an external
agent is not mixed at the molecular level, and the reactants
should be represented as individual phases, which interact
at the interface. In pharmaceutical forms, the active pharma-
ceutical ingredient (API) may exist in several states, which
may be modified as changes in temperature occur in the sys-
tem. Parallel to the physical transformation, processes of
chemical degradation can develop, which also modify the
structure of the API and even of excipients. In such scenario,
mathematical expressions describing the rate of degradation
will be only approximated.
In the evaluation of the reaction kinetics in heteroge-
neous systems, the only concentration of importance is
at the reaction interface, which cannot be quantified in a
practical way; for this reason, the way of monitoring the
development of the reaction is measuring the degree of
conversion (α) of the reagent or the product [7]. Consid-




= k T f α , 1
where α is the magnitude of the chemical or physical con-
version, t is the time, T is the temperature, f α is the
reaction model, and k T is the proportionality constant
whose value depends on temperature and is defined by
Arrhenius equation:
k T = Ae−Ea/RT , 2
where A is the collision factor, Ea is the activation energy,
R is the constant proportionality of the ideal gas, and T is
the system’s temperature.
The degree of transformation can be defined in different
ways, either as a decrease in the amount of the substance of




For the purposes of the present study, α is considered
to be
α = C0 − C
C0
, 4
where α corresponds to the extension of change in a spe-
cific parameter of interest, the amount of degraded sub-
stance for example; in this particular case, C0 is the
initial concentration of substance and C is the amount of
substance measured at time t [8].
For homogeneous systems, the chemical kinetics of
reactions can be classified as first, second, and third order;
in heterogeneous systems, models should be developed to
describe the phenomena of kinetic transformation, and three
main types of kinetic behaviors are identified and repre-
sented by isothermal curves α versus T : acceleration,
deceleration, and linear sigmoidal.
In acceleration models, the degree of conversion α
increases with time; on the contrary, in the deceleration
models, the conversion rate decreases over time; sigmoidal
ones share the characteristics of both and represent autocat-
alytic process. The three types of kinetics can spread on
dozens of heterogeneous reaction models. Frequently, exper-
imental data do not fit any model, or if it does, it will fit one of
them at the beginning of the process and other at the end.
The challenges increase when model fitting is performed on
experimental data obtained in a nonisothermal run at a single
heating rate, β [9].
To overcome this complexity, the isoconversion para-
digmwas developed: it allows the calculation of the Arrhenius
equation constants, without the need to determine the order
of the reactions.
1.4. Isoconversional Methods. The isoconversion is a method-
ology created by Kujirai and Akahira in 1925, who studied
the decomposition of materials under isothermal conditions,
allowing them the determination of the activation energy as a
function of mass loss; in 1948, Dakin proposed some kinetic
models in the decomposition of complex materials; and, in
the 1950s, instrumentation was generated that allowed the
study of materials under nonisothermal conditions.
Modern methods maintain the principle of isoconversion
through flexible integration procedures for the determination
of activation energy. Moreover, it has been observed that the
activation energy obtained from the free models is indepen-
dent of the heating rate, but certain studies indicate that there
would be dependence of the heating range.
The kinetic isoconversion methods are based on the
elimination of the reaction model from kinetic calcula-
tions. The principle states that the rate of conversion,
under certain environmental conditions, depends solely
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on temperature. For the experimental determination, it is
necessary to establish a specification (broken line in
Figure 1), an acceptation limit to which the samples must
not reach, in a determined time, in order to remain safe
and effective.
In plotting degradation versus time, the shape of the
curve would be the same at different temperatures, being
more pronounced at elevated temperatures and with a ten-
dency to look like a straight line as the temperature decreases
[10]. From Figure 1, it can be said that the lines k1 and k2




If the degradation value α is the same for the lines k1 and
k2, one has to
k1t1 = k2t2 6
It is possible to calculate the value of the kinetic constants
based on a fixed degradation limit, regardless of the shape of
the curve. Thereby, a sample submitted to intense conditions
of temperature and humidity will reach a predetermined
limit in a specific time. The isoconversion stability test uses
some samples as maintained at different temperature and
humidity conditions, in order to determine the values of
the kinetic constants at different temperatures [6, 11, 12].
Unlike the gaseous or solution state kinetics, where the mol-
ecules react according to a reaction order, in nonhomoge-
neous systems, the molecules are arranged in multiple
unbalanced states, characterized by their variable mobility,
where each one can react to form products under their own
kinetics. The kinetics of the set of states or phases is complex.
In this situation, the isoconversion method is advantageous
for the determination of degradation kinetics because it only
considers the time to reach the specification [13]. There are
some types of isoconversional methods.
Standard isoconversion method uses the logarithm of the
exponential relation between degradation and time of the
Arrhenius Equation, for data of an isothermal process, of
the function g α , which expresses the degree of conversion.
ln g α = ln A − Ea
RT
+ ln t 7
Friedman’s method is a differential method expressed as
ln dα
dt
= ln A f α − Ea
RT
8
Ozawa Flyn and Wall, who applies to data from noni-
sothermal process:
log g α = log AEa
Rβ
+ ln p x , 9
where p x is the integral function of Arrhenius, x is equal to
Ea/RT , and β = dT/dt [2].
1.5. Moisture Effect. Moisture has a significant effect on the
stability of the pharmaceutically active ingredient even if
the reactions do not involve water molecules. As the temper-
ature increases, the water content in the atmosphere for a
given relative humidity value increases; however, the water
activity depends only on the relative humidity (% RH) value
[14]. One of the main effects of the relative humidity value is
the loss or addition of water molecules of hydration in the
crystalline forms of the active principle; in certain cases, this
loss of water of hydration can result in the complete transfor-
mation of the API to the amorphous state, which may present
a higher instability than the crystalline forms. For a given
temperature, the effect of moisture on the kinetic constant
can be represented by the following equation:
ln k = B %RH + C 10
This expression is called moisture sensitivity equation,
where B and C are constants. The value of B usually ranges
from 0.00 to 0.09; for example, under conditions of 10%
RH, B will have a value of 0.00, and under conditions of
75% RH, B would have a value of 0.09.
1.6. Combining the Effect of Temperature and Relative
Humidity. The combination of Arrhenius equations and
moisture sensitivity [6] gives an equation that considers the
effects of temperature and humidity on API stability.
ln k = ln A − Ea
RT
+ B %RH 11
This equation states that the rate of degradation, or
kinetic constant, depends on temperature and relative
humidity.
Because the equation has 3 constants A, Ea, and B and
two independent variables, the minimum number of experi-
ments required to solve the equation is three, being necessary
to increase the number of points to improve the accuracy of
the measurements [13]. In most studies, two to three weeks










Figure 1: Relation between the degree of conversion and the time at
different temperatures (graph based on [9]).
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environmental conditions. Some authors suggest considering
the variation of 5°C and 5% of RH for 14-day assay.
These measurements can be used to estimate the isocon-
version time in each condition. (1) First, draw a line through
the data to find the intercept with the limit specification. (2)
The two points closest to the specification limit can be used
to interpolate or extrapolate the time to reach the specifica-
tion. (3) A single point closest to the specification can be used
to determine k = α/t.
To determine the relationship between the variables with
the degradation, two methodologies can be used: (1) trans-
form the Arrhenius equation to the linear form and deter-
mine the constants by least squares regression and (2) make
a least squares fit in the exponential form.
1.7. Accuracy of Accelerated Isoconversion Stability Studies.
The determination of the value of the constants in the
corrected Arrhenius equation for moisture is associated with
an imprecision value from the measurements. In addition,
extrapolation is required in the axes of temperature and
humidity, incorporating another imprecision factor. Apply-
ing an error propagation procedure in the corrected
Arrhenius equation is mathematically complicated; instead,
an approximation is used by simulation. The approach used
is the Monte Carlo method, which provides variations at each
temperature and relative humidity, within a certain range,
and makes a least squares fit with all possible combinations.
In the application of the simulation with the Monte Carlo
method, a normal distribution and its standard deviation
are assumed. The process comprises 5000 simulations, in
order to build confidence limits for kinetic parameters [15].
In the development of the isoconversion stability test, it is
necessary to consider the following: (i) the precision of the
analysis will affect the accuracy of the shelf life, the improved
result may increase the number of repetitions, but in many
cases, it will not be necessary. (ii) Greater extrapolation in
the magnitude of % RH or temperature generates a greater
error of the predictions, (iii) for certain API’s, broad extrapo-
lations provide an acceptable determination. (iv) Conditions
of low humidity levels and high temperatures can cause prob-
lems if physical changes are generated, such as dehydration
and changes of crystalline forms.
1.8. Nonisothermal Methods. As previously stated, stability
tests provide information on how the quality of an API,
excipient, or drug delivery system changes as a function
of time under the influence of environmental factors such
as temperature, humidity, and light, in order to establish
the shelf life of the compound and propose the best stor-
age conditions.
The factors influencing the reaction rate of homogeneous
systems, such as temperature, pressure, and composition, do
not include factors characteristic of heterogeneous systems
such as the matter transport between phases and the mode
of interaction between these phases.
This leads to the use of standard methods to determine
small changes in drug concentration, which have low sensi-
tivity and therefore require the previous dissolution of the
solid product, causing distortions in the test as a result of
the acceleration of the decomposition process when the com-
pound is solvated.
Applying a nonisothermal treatment by differential scan-
ning calorimetry would reduce the analysis period from
months or years to a few days and reduce the problems
related to the evaluation of heterogeneous systems.
In order to do that, some points have to be issued.
First, it is necessary to create a mathematical model that
could adjust to the kinetics that develops in condensed
phases; the second element to be considered is the effect
of the relative humidity on the reaction kinetics, and the
third one is the necessary time to carry out the determina-
tion of the stability.
The traditional kinetic models state out that their
postulates on the concentration monitoring as a function
of time consider the system as homogeneous and accept
the loss of precision by assuming a zero-order model for
all reactions.
For heterogeneous systems, kinetic studies monitor the
degraded fraction, α, as a function of time and reaction order
models are much more varied than for liquids. To deal with
the large number of models involved, isoconversional
methods have been developed, which do not need to consider
the reaction model, focusing instead on the failure time or
shelf life, tα, i.e., the time during the substance, which
undergoes decomposition as a result of the conditions under
which it is stored, is kept within acceptable limits.
The kinetic parameters of a decomposition reaction can
be estimated using differential scanning calorimetry (DSC).
If a sample is subjected to different heating rates, β, in
DSC, the maximum decomposition temperatures Tm
increase as β increases.
According to Kissinger’s method, if ln β/Tm2 is plotted
as a function of the inverse of Tm, the activation energy of the
reaction, Ea, can be determined from the slope of the line.
ln β
T2m










Once Ea is known, the value of A can be estimated by the
expression:
A = β Ea
RT2m
exp Ea/RTm 14
The values of the decomposition rate constant, k, can be
calculated for a reference temperature, T , by
log k = log A − Ea2 3RT 15
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Low Ea values would imply a lower energy barrier to be
overcome for degradation to occur and, therefore, less stabil-
ity; low values of k would indicate longer times until the
substance comes out of the specification by decomposition.
The shelf life of a drug delivery system is the period
during it remains under the acceptable limits, for example,
an API content≥ 95% (or a value of α = 0 05); it can be
calculated by
tα =
−ln 1 − α/100
Ae −Ea/RT
, 16
where the reference temperature, T , is 298.15K (25°C) [16].
The kinetic parameters and the shelf life time are used
to compare API from different batch, manufacturer, time,
or storage conditions and make inferences about their sta-
bility and decomposition progress. In the case of drug
delivery systems, decisions can be made about which for-
mulation has the greatest stability or whether a formula-
tion in the process of development is similar or not to a
market one, of known stability.
The validity of the predictions of shelf life must be
verified because the calculations are made by assuming
that (i) the reactions are of first order; (ii) the values of
the kinetic parameters are similar for the temperatures in
the study range; and (iii) the effect of moisture is not sig-
nificant. Studies that propose new methods of analysis or
that provide specific information on an active principle
such as kinetic parameters and degradation pathways are
very useful in the pharmaceutical industry because they
can save resources, as well as guarantee the safety, quality,
and effectiveness of medicines.
Thermal analysis techniques such as differential scan-
ning calorimetry (DSC) allow the characterization and
identification of physicochemical changes in the solid state
of different compounds, thus streamlining the process of
preformulation and development of drugs and substances
of pharmacological interest. Its use is not limited solely
to the determination of purity, polymorphs, solvates and
hydrates, melting point, and component quantification
but also allows the characterization of the surface proper-
ties of powders, such as humectants, adsorbents, and sur-
face energy, thus constituting a useful tool in decision
making in the case of problems related to the production
process.
Another advantage of using a nonisothermal method is
that it is not based on any assumptions about the reaction
mechanism and thus does not require any prior knowledge
of the initial concentration of the API, which eliminates the
prolonged reaction times and storage requirements required
by conventional techniques.
It also allows the saving of money, labor, and amount
of drug used and decreases the generation of waste, which
even lowers the cost of the drug, making it more accessible
for the population.
Finally, by combining isothermal isoconversional and
nonisothermal method, their individual limitations could be
overwhelmed, allowing a faster and accurate shelf life estima-
tion that could be contrasted against data obtained from
accelerated or long-term stability studies. This proposal is
schematized in Figure 2.
1.8.1. Isothermal Stage. Nanoparticles should be weighted in
18 open aluminum capsules for DSC; all the capsules of the
same type of nanoparticle (d1, d2, or d3) are placed in spe-
cially designed supports, subjecting the nanoparticles to the
established humidity and temperature conditions (3 different
conditions). Keep the nanoparticles to the selected condi-
tions during the selected time (3 storage times). Quantify
by HPLC the amount of API remaining in 3 capsules at 7,
14, and 21 days.
1.8.2. Nonisothermal Stage. For Tm determination, submit























Figure 2: Schematic representation of methodology combining isothermal isoconversional and nonisothermal approaches for the assessment
of shelf life in nanoparticles.
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heating rates (3 capsules for each speed). Calculate the kinetic
parameters for the isothermal and nonisothermal methods.
1.8.3. Accelerated Stability Study Stage. Another set of 12
samples will be subjected to 40°C and 75% RH in accelerated
traditional stability study. Samples will be taken at 1, 2, 3, and
6 months and analyzed for API content.
Using the API remaining quantity in each sample, corre-
sponding to each temporal point, elaborate confidence
hyperbola to establish the shelf life.
The accuracy of the estimated shelf life will be assessed by
comparison with long-term stability data. A mathematical
model to predict shelf life stability should be established.
2. Conclusions
The development of a fast and reliable method to assess shelf
life nanoparticles by isothermal and nonisothermal methods
allows to calculate its kinetic parameters and to establish a
mathematical model to estimate its shelf life.
The accuracy of mathematical model could be assessed
by comparison of predicted shelf life versus results coming
from long-term stability studies.
Isothermal isoconversional methods and nonisothermal
treatments could allow the establishment of mathematical
predictors of stability with less uncertainty than traditional
approach for nanoparticles.
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